Letter: vedolizumab or a second anti‐TNF—no difference in efficacy for primary biologic failures with IBD

LINKED CONTENT This article is linked to Rundquist et al papers. To view these articles, visit https://doi.org/10.1111/apt.16193 and https://doi.org/10.1111/apt.16352

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2021-05, Vol.53 (9), p.1044-1045
Main Authors: Demarzo, Maria Giulia, Bodini, Giorgia, Vanello, Mattia, Martini, Martina, Giannini, Edoardo G.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized
Biological Products - therapeutic use
Humans
Inflammatory Bowel Diseases - drug therapy
Pharmaceutical Preparations
Sweden
Tumor Necrosis Factor-alpha
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:LINKED CONTENT This article is linked to Rundquist et al papers. To view these articles, visit https://doi.org/10.1111/apt.16193 and https://doi.org/10.1111/apt.16352
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.16301